According to the European Society for Medical Oncology (ESMO) guidelines, in a given case of non-oncogene-addicted metastatic NSCLC, single-agent chemotherapy (GEM, vinorelbine, DOC, pemetrexed, the latter in a non-squamous NSCLC setting) can be considered in patients with Eastern Cooperative Oncology Group (ECOG) performance status 2 and PD-L1 < 50% [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.